




O I P E  
APR 13 2005  
PATENT & TRADEMARK OFFICE




## ATTACHMENT A




### AMENDMENTS TO THE CLAIMS



*Following herewith is a complete listing of the claims, including a marked copy of the currently amended claims.*

1. (Currently amended) A coumarin analog having the formula selected from the group consisting of: ~~NCP-014, NCP-014a, NCP-014b, NCP-023, NCP-023a, NCP-023b, NCP-023c, NCP-023d, NCP-023e, NCP-023f, NCP-023g, and NCP-023g~~









2. (Original) An anticoagulant composition comprising the coumarin analog of Claim 1 and a pharmaceutically acceptable vehicle, carrier or excipient.
3. (Original) An anticoagulant composition according to Claim 2 wherein the coumarin analog is included in an amount effective to inhibit coagulation of the blood in a patient in need of such therapy.
4. (Original) The anticoagulant composition according to Claim 2 further comprising a second compound having anticoagulant properties.

5. (Original) The anticoagulant composition according to Claim 4 wherein the second compound having anticoagulant properties is sodium warfarin.

6. (Original) A method of inhibiting or preventing blood coagulation in a patient in need of such therapy comprising administering an effective amount of the coumarin analog according to Claim 1.

7. (Original) A method of preventing blood coagulation in a patient in need of such therapy comprising administering the composition according to Claim 2 in an amount effective to achieve inhibition or prevention of blood coagulation.

8. (Withdrawn) A method of selecting coumarin analogs for effective anticoagulation therapy with a reduced risk of adverse side effects comprising obtaining candidate coumarin analogs having anticoagulation activity, introducing said candidate analogs to serum albumin in such a manner so that the binding location of the candidate coumarin analog to serum albumin can be determined, determining the location of the binding site of said candidate analog to serum albumin, and selecting said coumarin analogs which bind to serum albumin at a binding site different from that of sodium warfarin.

9. (Withdrawn) A coumarin analog obtained by the method of Claim 8.

10. (Withdrawn) An anticoagulant composition comprising the coumarin analog of Claim 9 and a pharmaceutically acceptable vehicle, carrier or excipient.